nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxymorphone—CYP3A4—Vandetanib—thyroid cancer	0.101	0.286	CbGbCtD
Oxymorphone—CYP2D6—Sorafenib—thyroid cancer	0.0953	0.272	CbGbCtD
Oxymorphone—CYP3A4—Sorafenib—thyroid cancer	0.0606	0.173	CbGbCtD
Oxymorphone—CYP2D6—Doxorubicin—thyroid cancer	0.0578	0.165	CbGbCtD
Oxymorphone—CYP3A4—Doxorubicin—thyroid cancer	0.0368	0.105	CbGbCtD
Oxymorphone—Altered state of consciousness—Vandetanib—thyroid cancer	0.0276	0.0426	CcSEcCtD
Oxymorphone—Ileus—Vandetanib—thyroid cancer	0.018	0.0278	CcSEcCtD
Oxymorphone—Respiratory distress—Sorafenib—thyroid cancer	0.0136	0.0209	CcSEcCtD
Oxymorphone—Depressed level of consciousness—Vandetanib—thyroid cancer	0.0123	0.019	CcSEcCtD
Oxymorphone—Lethargy—Vandetanib—thyroid cancer	0.00945	0.0146	CcSEcCtD
Oxymorphone—Drug interaction—Sorafenib—thyroid cancer	0.00928	0.0143	CcSEcCtD
Oxymorphone—Dehydration—Vandetanib—thyroid cancer	0.00862	0.0133	CcSEcCtD
Oxymorphone—Bronchospasm—Vandetanib—thyroid cancer	0.00788	0.0121	CcSEcCtD
Oxymorphone—Weight decreased—Vandetanib—thyroid cancer	0.00724	0.0112	CcSEcCtD
Oxymorphone—Pneumonia—Vandetanib—thyroid cancer	0.00718	0.0111	CcSEcCtD
Oxymorphone—Bradycardia—Vandetanib—thyroid cancer	0.00652	0.0101	CcSEcCtD
Oxymorphone—Pneumothorax—Epirubicin—thyroid cancer	0.00639	0.00986	CcSEcCtD
Oxymorphone—Urinary tract disorder—Vandetanib—thyroid cancer	0.00633	0.00975	CcSEcCtD
Oxymorphone—Urethral disorder—Vandetanib—thyroid cancer	0.00628	0.00968	CcSEcCtD
Oxymorphone—Visual impairment—Vandetanib—thyroid cancer	0.00618	0.00952	CcSEcCtD
Oxymorphone—Eye disorder—Vandetanib—thyroid cancer	0.00599	0.00923	CcSEcCtD
Oxymorphone—Cardiac disorder—Vandetanib—thyroid cancer	0.00595	0.00917	CcSEcCtD
Oxymorphone—Pneumothorax—Doxorubicin—thyroid cancer	0.00592	0.00912	CcSEcCtD
Oxymorphone—Angiopathy—Vandetanib—thyroid cancer	0.00581	0.00896	CcSEcCtD
Oxymorphone—Dehydration—Sorafenib—thyroid cancer	0.00581	0.00896	CcSEcCtD
Oxymorphone—Mediastinal disorder—Vandetanib—thyroid cancer	0.00578	0.0089	CcSEcCtD
Oxymorphone—Mental disorder—Vandetanib—thyroid cancer	0.00561	0.00865	CcSEcCtD
Oxymorphone—Malnutrition—Vandetanib—thyroid cancer	0.00558	0.0086	CcSEcCtD
Oxymorphone—Vision blurred—Vandetanib—thyroid cancer	0.00526	0.0081	CcSEcCtD
Oxymorphone—Loss of consciousness—Vandetanib—thyroid cancer	0.0049	0.00756	CcSEcCtD
Oxymorphone—Weight decreased—Sorafenib—thyroid cancer	0.00489	0.00753	CcSEcCtD
Oxymorphone—Pneumonia—Sorafenib—thyroid cancer	0.00484	0.00747	CcSEcCtD
Oxymorphone—Convulsion—Vandetanib—thyroid cancer	0.00483	0.00745	CcSEcCtD
Oxymorphone—Hypertension—Vandetanib—thyroid cancer	0.00482	0.00742	CcSEcCtD
Oxymorphone—Chest pain—Vandetanib—thyroid cancer	0.00475	0.00732	CcSEcCtD
Oxymorphone—Anxiety—Vandetanib—thyroid cancer	0.00473	0.00729	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00472	0.00727	CcSEcCtD
Oxymorphone—Dry mouth—Vandetanib—thyroid cancer	0.00465	0.00716	CcSEcCtD
Oxymorphone—Oedema—Vandetanib—thyroid cancer	0.00455	0.00702	CcSEcCtD
Oxymorphone—Lung disorder—Epirubicin—thyroid cancer	0.0045	0.00693	CcSEcCtD
Oxymorphone—Ileus—Epirubicin—thyroid cancer	0.0045	0.00693	CcSEcCtD
Oxymorphone—Nervous system disorder—Vandetanib—thyroid cancer	0.00447	0.00688	CcSEcCtD
Oxymorphone—Skin disorder—Vandetanib—thyroid cancer	0.00442	0.00682	CcSEcCtD
Oxymorphone—Dermatitis atopic—Epirubicin—thyroid cancer	0.0043	0.00662	CcSEcCtD
Oxymorphone—Urinary tract disorder—Sorafenib—thyroid cancer	0.00427	0.00658	CcSEcCtD
Oxymorphone—Urethral disorder—Sorafenib—thyroid cancer	0.00424	0.00653	CcSEcCtD
Oxymorphone—Lung disorder—Doxorubicin—thyroid cancer	0.00416	0.00641	CcSEcCtD
Oxymorphone—Ileus—Doxorubicin—thyroid cancer	0.00416	0.00641	CcSEcCtD
Oxymorphone—Insomnia—Vandetanib—thyroid cancer	0.00412	0.00635	CcSEcCtD
Oxymorphone—Dyspnoea—Vandetanib—thyroid cancer	0.00406	0.00626	CcSEcCtD
Oxymorphone—Cardiac disorder—Sorafenib—thyroid cancer	0.00401	0.00618	CcSEcCtD
Oxymorphone—Flushing—Sorafenib—thyroid cancer	0.00401	0.00618	CcSEcCtD
Oxymorphone—Dyspepsia—Vandetanib—thyroid cancer	0.00401	0.00618	CcSEcCtD
Oxymorphone—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00398	0.00613	CcSEcCtD
Oxymorphone—Decreased appetite—Vandetanib—thyroid cancer	0.00396	0.0061	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00393	0.00606	CcSEcCtD
Oxymorphone—Fatigue—Vandetanib—thyroid cancer	0.00393	0.00605	CcSEcCtD
Oxymorphone—Angiopathy—Sorafenib—thyroid cancer	0.00392	0.00605	CcSEcCtD
Oxymorphone—Immune system disorder—Sorafenib—thyroid cancer	0.0039	0.00602	CcSEcCtD
Oxymorphone—Mediastinal disorder—Sorafenib—thyroid cancer	0.0039	0.006	CcSEcCtD
Oxymorphone—Constipation—Vandetanib—thyroid cancer	0.00389	0.006	CcSEcCtD
Oxymorphone—Pain—Vandetanib—thyroid cancer	0.00389	0.006	CcSEcCtD
Oxymorphone—Mental disorder—Sorafenib—thyroid cancer	0.00379	0.00584	CcSEcCtD
Oxymorphone—Malnutrition—Sorafenib—thyroid cancer	0.00376	0.0058	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Vandetanib—thyroid cancer	0.00372	0.00574	CcSEcCtD
Oxymorphone—Abdominal pain—Vandetanib—thyroid cancer	0.0036	0.00555	CcSEcCtD
Oxymorphone—Body temperature increased—Vandetanib—thyroid cancer	0.0036	0.00555	CcSEcCtD
Oxymorphone—Oliguria—Epirubicin—thyroid cancer	0.00345	0.00532	CcSEcCtD
Oxymorphone—Syncope—Sorafenib—thyroid cancer	0.00337	0.0052	CcSEcCtD
Oxymorphone—Loss of consciousness—Sorafenib—thyroid cancer	0.00331	0.0051	CcSEcCtD
Oxymorphone—Asthenia—Vandetanib—thyroid cancer	0.00327	0.00503	CcSEcCtD
Oxymorphone—Hypertension—Sorafenib—thyroid cancer	0.00325	0.00501	CcSEcCtD
Oxymorphone—Pruritus—Vandetanib—thyroid cancer	0.00322	0.00496	CcSEcCtD
Oxymorphone—Oliguria—Doxorubicin—thyroid cancer	0.00319	0.00492	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00318	0.0049	CcSEcCtD
Oxymorphone—Injection site reaction—Epirubicin—thyroid cancer	0.00316	0.00487	CcSEcCtD
Oxymorphone—Dry mouth—Sorafenib—thyroid cancer	0.00313	0.00483	CcSEcCtD
Oxymorphone—Diarrhoea—Vandetanib—thyroid cancer	0.00312	0.0048	CcSEcCtD
Oxymorphone—Shock—Sorafenib—thyroid cancer	0.00302	0.00466	CcSEcCtD
Oxymorphone—Nervous system disorder—Sorafenib—thyroid cancer	0.00301	0.00464	CcSEcCtD
Oxymorphone—Dizziness—Vandetanib—thyroid cancer	0.00301	0.00464	CcSEcCtD
Oxymorphone—Skin disorder—Sorafenib—thyroid cancer	0.00298	0.0046	CcSEcCtD
Oxymorphone—Anorexia—Sorafenib—thyroid cancer	0.00293	0.00451	CcSEcCtD
Oxymorphone—Injection site reaction—Doxorubicin—thyroid cancer	0.00293	0.00451	CcSEcCtD
Oxymorphone—Vomiting—Vandetanib—thyroid cancer	0.0029	0.00446	CcSEcCtD
Oxymorphone—Dermatitis—Vandetanib—thyroid cancer	0.00287	0.00442	CcSEcCtD
Oxymorphone—Headache—Vandetanib—thyroid cancer	0.00285	0.0044	CcSEcCtD
Oxymorphone—Mental disability—Epirubicin—thyroid cancer	0.00276	0.00426	CcSEcCtD
Oxymorphone—Dyspnoea—Sorafenib—thyroid cancer	0.00274	0.00422	CcSEcCtD
Oxymorphone—Nausea—Vandetanib—thyroid cancer	0.0027	0.00417	CcSEcCtD
Oxymorphone—Dyspepsia—Sorafenib—thyroid cancer	0.0027	0.00417	CcSEcCtD
Oxymorphone—Decreased appetite—Sorafenib—thyroid cancer	0.00267	0.00412	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00265	0.00409	CcSEcCtD
Oxymorphone—Fatigue—Sorafenib—thyroid cancer	0.00265	0.00408	CcSEcCtD
Oxymorphone—Constipation—Sorafenib—thyroid cancer	0.00263	0.00405	CcSEcCtD
Oxymorphone—Pain—Sorafenib—thyroid cancer	0.00263	0.00405	CcSEcCtD
Oxymorphone—Mental disability—Doxorubicin—thyroid cancer	0.00255	0.00394	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00251	0.00387	CcSEcCtD
Oxymorphone—Hot flush—Epirubicin—thyroid cancer	0.00247	0.00381	CcSEcCtD
Oxymorphone—Menopausal symptoms—Epirubicin—thyroid cancer	0.00245	0.00377	CcSEcCtD
Oxymorphone—Urticaria—Sorafenib—thyroid cancer	0.00244	0.00376	CcSEcCtD
Oxymorphone—Abdominal pain—Sorafenib—thyroid cancer	0.00243	0.00374	CcSEcCtD
Oxymorphone—Body temperature increased—Sorafenib—thyroid cancer	0.00243	0.00374	CcSEcCtD
Oxymorphone—Lethargy—Epirubicin—thyroid cancer	0.00236	0.00363	CcSEcCtD
Oxymorphone—Diplopia—Epirubicin—thyroid cancer	0.00231	0.00356	CcSEcCtD
Oxymorphone—Hot flush—Doxorubicin—thyroid cancer	0.00228	0.00352	CcSEcCtD
Oxymorphone—Menopausal symptoms—Doxorubicin—thyroid cancer	0.00226	0.00349	CcSEcCtD
Oxymorphone—Hypersensitivity—Sorafenib—thyroid cancer	0.00226	0.00349	CcSEcCtD
Oxymorphone—Asthenia—Sorafenib—thyroid cancer	0.0022	0.0034	CcSEcCtD
Oxymorphone—Lethargy—Doxorubicin—thyroid cancer	0.00218	0.00336	CcSEcCtD
Oxymorphone—Pruritus—Sorafenib—thyroid cancer	0.00217	0.00335	CcSEcCtD
Oxymorphone—Dehydration—Epirubicin—thyroid cancer	0.00215	0.00331	CcSEcCtD
Oxymorphone—Diplopia—Doxorubicin—thyroid cancer	0.00214	0.00329	CcSEcCtD
Oxymorphone—Orthostatic hypotension—Epirubicin—thyroid cancer	0.00211	0.00325	CcSEcCtD
Oxymorphone—Diarrhoea—Sorafenib—thyroid cancer	0.0021	0.00324	CcSEcCtD
Oxymorphone—Dizziness—Sorafenib—thyroid cancer	0.00203	0.00313	CcSEcCtD
Oxymorphone—Abdominal distension—Epirubicin—thyroid cancer	0.00201	0.0031	CcSEcCtD
Oxymorphone—Dehydration—Doxorubicin—thyroid cancer	0.00199	0.00306	CcSEcCtD
Oxymorphone—Vomiting—Sorafenib—thyroid cancer	0.00195	0.00301	CcSEcCtD
Oxymorphone—Orthostatic hypotension—Doxorubicin—thyroid cancer	0.00195	0.00301	CcSEcCtD
Oxymorphone—Dermatitis—Sorafenib—thyroid cancer	0.00193	0.00298	CcSEcCtD
Oxymorphone—Headache—Sorafenib—thyroid cancer	0.00192	0.00297	CcSEcCtD
Oxymorphone—Abdominal distension—Doxorubicin—thyroid cancer	0.00186	0.00287	CcSEcCtD
Oxymorphone—Nausea—Sorafenib—thyroid cancer	0.00182	0.00281	CcSEcCtD
Oxymorphone—Weight decreased—Epirubicin—thyroid cancer	0.00181	0.00278	CcSEcCtD
Oxymorphone—Pneumonia—Epirubicin—thyroid cancer	0.00179	0.00276	CcSEcCtD
Oxymorphone—Weight decreased—Doxorubicin—thyroid cancer	0.00167	0.00258	CcSEcCtD
Oxymorphone—Pneumonia—Doxorubicin—thyroid cancer	0.00166	0.00255	CcSEcCtD
Oxymorphone—Bradycardia—Epirubicin—thyroid cancer	0.00163	0.00251	CcSEcCtD
Oxymorphone—Urinary tract disorder—Epirubicin—thyroid cancer	0.00158	0.00243	CcSEcCtD
Oxymorphone—Urethral disorder—Epirubicin—thyroid cancer	0.00157	0.00241	CcSEcCtD
Oxymorphone—Visual impairment—Epirubicin—thyroid cancer	0.00154	0.00237	CcSEcCtD
Oxymorphone—Bradycardia—Doxorubicin—thyroid cancer	0.0015	0.00232	CcSEcCtD
Oxymorphone—Eye disorder—Epirubicin—thyroid cancer	0.00149	0.0023	CcSEcCtD
Oxymorphone—Cardiac disorder—Epirubicin—thyroid cancer	0.00148	0.00229	CcSEcCtD
Oxymorphone—Flushing—Epirubicin—thyroid cancer	0.00148	0.00229	CcSEcCtD
Oxymorphone—Urinary tract disorder—Doxorubicin—thyroid cancer	0.00146	0.00225	CcSEcCtD
Oxymorphone—Angiopathy—Epirubicin—thyroid cancer	0.00145	0.00223	CcSEcCtD
Oxymorphone—Urethral disorder—Doxorubicin—thyroid cancer	0.00145	0.00223	CcSEcCtD
Oxymorphone—Immune system disorder—Epirubicin—thyroid cancer	0.00144	0.00222	CcSEcCtD
Oxymorphone—Mediastinal disorder—Epirubicin—thyroid cancer	0.00144	0.00222	CcSEcCtD
Oxymorphone—Visual impairment—Doxorubicin—thyroid cancer	0.00142	0.0022	CcSEcCtD
Oxymorphone—Mental disorder—Epirubicin—thyroid cancer	0.0014	0.00216	CcSEcCtD
Oxymorphone—Malnutrition—Epirubicin—thyroid cancer	0.00139	0.00214	CcSEcCtD
Oxymorphone—Eye disorder—Doxorubicin—thyroid cancer	0.00138	0.00213	CcSEcCtD
Oxymorphone—Flushing—Doxorubicin—thyroid cancer	0.00137	0.00211	CcSEcCtD
Oxymorphone—Cardiac disorder—Doxorubicin—thyroid cancer	0.00137	0.00211	CcSEcCtD
Oxymorphone—Flatulence—Epirubicin—thyroid cancer	0.00137	0.00211	CcSEcCtD
Oxymorphone—Tension—Epirubicin—thyroid cancer	0.00136	0.0021	CcSEcCtD
Oxymorphone—Nervousness—Epirubicin—thyroid cancer	0.00135	0.00208	CcSEcCtD
Oxymorphone—Angiopathy—Doxorubicin—thyroid cancer	0.00134	0.00207	CcSEcCtD
Oxymorphone—Immune system disorder—Doxorubicin—thyroid cancer	0.00134	0.00206	CcSEcCtD
Oxymorphone—Mediastinal disorder—Doxorubicin—thyroid cancer	0.00133	0.00205	CcSEcCtD
Oxymorphone—Vision blurred—Epirubicin—thyroid cancer	0.00131	0.00202	CcSEcCtD
Oxymorphone—Mental disorder—Doxorubicin—thyroid cancer	0.0013	0.002	CcSEcCtD
Oxymorphone—Malnutrition—Doxorubicin—thyroid cancer	0.00129	0.00198	CcSEcCtD
Oxymorphone—Agitation—Epirubicin—thyroid cancer	0.00128	0.00197	CcSEcCtD
Oxymorphone—Flatulence—Doxorubicin—thyroid cancer	0.00127	0.00195	CcSEcCtD
Oxymorphone—Tension—Doxorubicin—thyroid cancer	0.00126	0.00195	CcSEcCtD
Oxymorphone—Nervousness—Doxorubicin—thyroid cancer	0.00125	0.00193	CcSEcCtD
Oxymorphone—Vertigo—Epirubicin—thyroid cancer	0.00125	0.00193	CcSEcCtD
Oxymorphone—Syncope—Epirubicin—thyroid cancer	0.00125	0.00192	CcSEcCtD
Oxymorphone—Palpitations—Epirubicin—thyroid cancer	0.00123	0.00189	CcSEcCtD
Oxymorphone—Loss of consciousness—Epirubicin—thyroid cancer	0.00122	0.00188	CcSEcCtD
Oxymorphone—Vision blurred—Doxorubicin—thyroid cancer	0.00121	0.00187	CcSEcCtD
Oxymorphone—Convulsion—Epirubicin—thyroid cancer	0.00121	0.00186	CcSEcCtD
Oxymorphone—Hypertension—Epirubicin—thyroid cancer	0.0012	0.00185	CcSEcCtD
Oxymorphone—Chest pain—Epirubicin—thyroid cancer	0.00118	0.00182	CcSEcCtD
Oxymorphone—Agitation—Doxorubicin—thyroid cancer	0.00118	0.00182	CcSEcCtD
Oxymorphone—Anxiety—Epirubicin—thyroid cancer	0.00118	0.00182	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.00118	0.00181	CcSEcCtD
Oxymorphone—Dry mouth—Epirubicin—thyroid cancer	0.00116	0.00178	CcSEcCtD
Oxymorphone—Vertigo—Doxorubicin—thyroid cancer	0.00116	0.00178	CcSEcCtD
Oxymorphone—Syncope—Doxorubicin—thyroid cancer	0.00115	0.00178	CcSEcCtD
Oxymorphone—Confusional state—Epirubicin—thyroid cancer	0.00114	0.00176	CcSEcCtD
Oxymorphone—Palpitations—Doxorubicin—thyroid cancer	0.00114	0.00175	CcSEcCtD
Oxymorphone—Oedema—Epirubicin—thyroid cancer	0.00114	0.00175	CcSEcCtD
Oxymorphone—Loss of consciousness—Doxorubicin—thyroid cancer	0.00113	0.00174	CcSEcCtD
Oxymorphone—Shock—Epirubicin—thyroid cancer	0.00112	0.00172	CcSEcCtD
Oxymorphone—Convulsion—Doxorubicin—thyroid cancer	0.00112	0.00172	CcSEcCtD
Oxymorphone—Nervous system disorder—Epirubicin—thyroid cancer	0.00111	0.00172	CcSEcCtD
Oxymorphone—Hypertension—Doxorubicin—thyroid cancer	0.00111	0.00171	CcSEcCtD
Oxymorphone—Tachycardia—Epirubicin—thyroid cancer	0.00111	0.00171	CcSEcCtD
Oxymorphone—Skin disorder—Epirubicin—thyroid cancer	0.0011	0.0017	CcSEcCtD
Oxymorphone—Hyperhidrosis—Epirubicin—thyroid cancer	0.0011	0.00169	CcSEcCtD
Oxymorphone—Chest pain—Doxorubicin—thyroid cancer	0.0011	0.00169	CcSEcCtD
Oxymorphone—Anxiety—Doxorubicin—thyroid cancer	0.00109	0.00168	CcSEcCtD
Oxymorphone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.00109	0.00168	CcSEcCtD
Oxymorphone—Anorexia—Epirubicin—thyroid cancer	0.00108	0.00167	CcSEcCtD
Oxymorphone—Dry mouth—Doxorubicin—thyroid cancer	0.00107	0.00165	CcSEcCtD
Oxymorphone—Hypotension—Epirubicin—thyroid cancer	0.00106	0.00163	CcSEcCtD
Oxymorphone—Confusional state—Doxorubicin—thyroid cancer	0.00106	0.00163	CcSEcCtD
Oxymorphone—Oedema—Doxorubicin—thyroid cancer	0.00105	0.00162	CcSEcCtD
Oxymorphone—Shock—Doxorubicin—thyroid cancer	0.00103	0.00159	CcSEcCtD
Oxymorphone—Nervous system disorder—Doxorubicin—thyroid cancer	0.00103	0.00159	CcSEcCtD
Oxymorphone—Insomnia—Epirubicin—thyroid cancer	0.00103	0.00158	CcSEcCtD
Oxymorphone—Tachycardia—Doxorubicin—thyroid cancer	0.00103	0.00158	CcSEcCtD
Oxymorphone—Skin disorder—Doxorubicin—thyroid cancer	0.00102	0.00157	CcSEcCtD
Oxymorphone—Hyperhidrosis—Doxorubicin—thyroid cancer	0.00102	0.00156	CcSEcCtD
Oxymorphone—Dyspnoea—Epirubicin—thyroid cancer	0.00101	0.00156	CcSEcCtD
Oxymorphone—Somnolence—Epirubicin—thyroid cancer	0.00101	0.00156	CcSEcCtD
Oxymorphone—Anorexia—Doxorubicin—thyroid cancer	0.001	0.00154	CcSEcCtD
Oxymorphone—Dyspepsia—Epirubicin—thyroid cancer	0.000999	0.00154	CcSEcCtD
Oxymorphone—Decreased appetite—Epirubicin—thyroid cancer	0.000987	0.00152	CcSEcCtD
Oxymorphone—Hypotension—Doxorubicin—thyroid cancer	0.000981	0.00151	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.00098	0.00151	CcSEcCtD
Oxymorphone—Fatigue—Epirubicin—thyroid cancer	0.000979	0.00151	CcSEcCtD
Oxymorphone—Pain—Epirubicin—thyroid cancer	0.000971	0.0015	CcSEcCtD
Oxymorphone—Constipation—Epirubicin—thyroid cancer	0.000971	0.0015	CcSEcCtD
Oxymorphone—Insomnia—Doxorubicin—thyroid cancer	0.00095	0.00146	CcSEcCtD
Oxymorphone—Dyspnoea—Doxorubicin—thyroid cancer	0.000936	0.00144	CcSEcCtD
Oxymorphone—Feeling abnormal—Epirubicin—thyroid cancer	0.000935	0.00144	CcSEcCtD
Oxymorphone—Somnolence—Doxorubicin—thyroid cancer	0.000934	0.00144	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000928	0.00143	CcSEcCtD
Oxymorphone—Dyspepsia—Doxorubicin—thyroid cancer	0.000925	0.00142	CcSEcCtD
Oxymorphone—Decreased appetite—Doxorubicin—thyroid cancer	0.000913	0.00141	CcSEcCtD
Oxymorphone—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000907	0.0014	CcSEcCtD
Oxymorphone—Fatigue—Doxorubicin—thyroid cancer	0.000906	0.0014	CcSEcCtD
Oxymorphone—Urticaria—Epirubicin—thyroid cancer	0.000902	0.00139	CcSEcCtD
Oxymorphone—Pain—Doxorubicin—thyroid cancer	0.000898	0.00138	CcSEcCtD
Oxymorphone—Constipation—Doxorubicin—thyroid cancer	0.000898	0.00138	CcSEcCtD
Oxymorphone—Body temperature increased—Epirubicin—thyroid cancer	0.000897	0.00138	CcSEcCtD
Oxymorphone—Abdominal pain—Epirubicin—thyroid cancer	0.000897	0.00138	CcSEcCtD
Oxymorphone—Feeling abnormal—Doxorubicin—thyroid cancer	0.000866	0.00133	CcSEcCtD
Oxymorphone—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000859	0.00132	CcSEcCtD
Oxymorphone—Hypersensitivity—Epirubicin—thyroid cancer	0.000836	0.00129	CcSEcCtD
Oxymorphone—Urticaria—Doxorubicin—thyroid cancer	0.000834	0.00129	CcSEcCtD
Oxymorphone—Abdominal pain—Doxorubicin—thyroid cancer	0.00083	0.00128	CcSEcCtD
Oxymorphone—Body temperature increased—Doxorubicin—thyroid cancer	0.00083	0.00128	CcSEcCtD
Oxymorphone—Asthenia—Epirubicin—thyroid cancer	0.000814	0.00126	CcSEcCtD
Oxymorphone—Pruritus—Epirubicin—thyroid cancer	0.000803	0.00124	CcSEcCtD
Oxymorphone—Diarrhoea—Epirubicin—thyroid cancer	0.000777	0.0012	CcSEcCtD
Oxymorphone—Hypersensitivity—Doxorubicin—thyroid cancer	0.000774	0.00119	CcSEcCtD
Oxymorphone—Asthenia—Doxorubicin—thyroid cancer	0.000754	0.00116	CcSEcCtD
Oxymorphone—Dizziness—Epirubicin—thyroid cancer	0.000751	0.00116	CcSEcCtD
Oxymorphone—Pruritus—Doxorubicin—thyroid cancer	0.000743	0.00115	CcSEcCtD
Oxymorphone—Vomiting—Epirubicin—thyroid cancer	0.000722	0.00111	CcSEcCtD
Oxymorphone—Diarrhoea—Doxorubicin—thyroid cancer	0.000719	0.00111	CcSEcCtD
Oxymorphone—Dermatitis—Epirubicin—thyroid cancer	0.000715	0.0011	CcSEcCtD
Oxymorphone—Headache—Epirubicin—thyroid cancer	0.000711	0.0011	CcSEcCtD
Oxymorphone—Dizziness—Doxorubicin—thyroid cancer	0.000695	0.00107	CcSEcCtD
Oxymorphone—Nausea—Epirubicin—thyroid cancer	0.000674	0.00104	CcSEcCtD
Oxymorphone—Vomiting—Doxorubicin—thyroid cancer	0.000668	0.00103	CcSEcCtD
Oxymorphone—Dermatitis—Doxorubicin—thyroid cancer	0.000662	0.00102	CcSEcCtD
Oxymorphone—Headache—Doxorubicin—thyroid cancer	0.000658	0.00101	CcSEcCtD
Oxymorphone—Nausea—Doxorubicin—thyroid cancer	0.000624	0.000961	CcSEcCtD
